Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical ...
Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...
Scientists at the Department of Energy (DOE)'s Oak Ridge National Laboratory (ORNL) have shown that more than 93% of possible ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
In a paper, published on 24 August, scientists from the National Agri-Food and Biomanufacturing Institute genetically ...
The CRISPR gene editing market is estimated at USD 4 billion in 2025 and is projected to reach USD 22 billion by 2035, expanding at a CAGR of 18.6% during the forecast period 2026–2035. The market is ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN
4 gene-editing biotech stocks worth watching for long-term gains
Gene editing is emerging as a potentially transformative approach to medicine because it seeks to address disease at its ...
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...
It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results